Shared spine · Technology

Detection is our discipline.

We develop the core technologies of molecular diagnostics and the computational tools that sharpen them. Each is a capability we build, refine and put to work — first in our own research, then in our partners’ programs.

See what we deliver See our research
Proprietary OdigOS · CRISPR detection · Multiplex design · PCR · Isothermal · Extraction · NGS
Hyderabad, Telangana, India
Proprietary

The technologies we own.

Three capabilities we developed ourselves — and the reason a new panel is a guide redesign rather than a new assay.

Proprietary

OdigOS — guide RNA design

The engine that makes multiplexing tractable. OdigOS is our in-house guide RNA design engine, tuned for pathogen and resistance-gene targets. It ranks candidate guides by predicted on-target activity and off-target risk, and screens designs against curated sequence databases for inclusivity and exclusivity before anything reaches the bench.

That matters because it changes what a new panel costs to build. With a design engine, adding a target is a guide redesign. Without one, it is a new assay.

Proprietary

CRISPR detection

Programmable specificity, without the instrument. CRISPR detection turns a sequence into a signal. A guide RNA directs a Cas effector to your target; recognition activates collateral cleavage of a reporter, which produces a visible line on a lateral-flow strip or a fluorescent signal. Because specificity comes from the guide, a new target is a new guide rather than a new assay.

  • Cas12a assays — for DNA targets, read by lateral flow or fluorescence
  • Cas13a assays — for RNA targets, with transcription upstream of detection
  • Mismatch-engineered guides — where a single-nucleotide difference must be resolved, e.g. distinguishing a resistance allele from wild type
  • Multiplex panels — designed with OdigOS
You receiveGuide sequences and design rationale, reporter and readout configuration, optimized reaction conditions, analytical performance data, and an SOP.
Proprietary

Multiplex design

One sample, many answers, no sensitivity penalty. Multiplexing is a design discipline, not a chemistry. Channels compete for the same reagents, primers cross-react, and a panel that works at high concentration can lose its weakest target at the limit of detection. We balance primer and probe chemistry across channels, include an internal amplification control, and characterize each target both alone and in the panel.

You receivePer-channel and panel-level performance data — so a claim of “multiplexed without loss of sensitivity” is something you can show rather than assert.
Core capabilities

Four that complete the path.

The workhorses. Engineered for the samples, operators and conditions your test will actually meet.

Core

PCR, qPCR and RT-PCR

The workhorse, engineered to hold up in real samples. We develop singleplex and multiplex PCR, qPCR and RT-PCR assays for DNA and RNA targets, designed around the matrix they will actually see — from pristine to profoundly difficult.

You receive: primer and probe sequences with design rationale, optimized cycling conditions, LOD characterization, and an SOP.

Core

Isothermal amplification

Amplification without a thermal cycler. Recombinase polymerase amplification and LAMP copy a target at a constant temperature, which removes the instrument that keeps molecular testing inside a laboratory. RPA runs at 37 to 42 °C and amplifies in minutes. LAMP runs at 60 to 65 °C and uses four to six primers per target, which makes design more demanding but tolerates crude samples well.

Where it fits: near-patient testing, veterinary and aquaculture field use, food and water testing, and any setting where a PCR laboratory is not available.

Core

Sample preparation and extraction

Stop losing sensitivity to your sample. Every reliable result starts with clean material. Our magnetic-bead and column methods recover amplification-ready nucleic acid from demanding matrices at consistent yield and purity.

You receive: an optimized extraction protocol for your matrix, yield and purity data, and an SOP.

Core

Genomics, NGS and bioinformatics

Sequence evidence that keeps assays accurate as pathogens change. Our NGS support runs from library preparation through interpretation, compatible with Illumina and Nanopore, and includes sequencing coordination, QC and demultiplexing.

The bioinformatics matters more than the sequencing. Every assay we design is checked in silico against the diversity of its target — inclusivity against known sequence variation, exclusivity against near neighbors — and resistance-gene panels are designed against curated reference databases rather than individual sequences.

You receive: processed data, analysis reports, and the in-silico design evidence supporting your assay’s inclusivity and exclusivity claims.

Isothermal reagents currently require cold-chain storage. Room-temperature lyophilized formulations are in development.

Next step

Put the technology to work on your program.

Tell us the target and the sample type. We will come back within one business day with a feasibility view and a likely development path.

Start a conversation See what we deliver